Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kaketsuken Denies Unauthorized Manufacturing or Cover-up, Blames Ambiguity in Approval Doc
Vaccine and blood product maker Kaketsuken on October 18 denied the health ministry’s claim that it used an unauthorized method to manufacture its Japanese encephalitis vaccine Encevac, contending that the regulator misinterpreted an ambiguous statement in its approval document. Motoharu…
To read the full story
Related Article
- Kaketsuken Wraps Up Blanket Re-Inspection, Says There’s No Quality or Safety Concern
December 6, 2016
- Health Minister Nudges Kaketsuken on Biz Handover to Astellas
October 19, 2016
- MHLW to Consider Additional Penalties for Kaketsuken after Reviewing Its Report: Minister Shiozaki
October 11, 2016
- Kaketsuken Faces Another Penalty over Encephalitis Vaccine Manufacturing
October 5, 2016
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…